Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Mayzent (siponimod) for the Treatment of Multiple Sclerosis

Drug Name

Mayzent® (siponimod)

Developer

Novartis

Therapy Class

Sphingosine 1-phosphate receptor modulator

Product Description

2:1 co-crystal of siponimod and fumaric acid

Current Indication

Relapsing forms of multiple sclerosis

Market Sector

CNS

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top